Klotho Neurosciences, Inc.
NASDAQ Global MarketTotal Valuation
Klotho Neurosciences, Inc. carries a market capitalization of 6.26M, placing it among publicly traded companies globally. Its enterprise value stands at -7.35M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.26M |
| Enterprise Value | -7.35M |
Share Statistics
Klotho Neurosciences, Inc. currently has 70.33M shares outstanding.
| Shares Outstanding | 70.33M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Klotho Neurosciences, Inc. maintains a current ratio of 83.69, meaning it holds 83.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 83.69 |
| Quick Ratio | 82.76 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1.90 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -180.10 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Klotho Neurosciences, Inc.'s stock has gained approximately 336.54822% over the past 52 weeks. The 50-day moving average sits at 0.09, while the 200-day moving average is 0.15.
| Beta (5Y) | N/A |
| 52-Week Price Change | 336.54822% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 0.15 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -7.18M, while operating income came in at -7.18M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -7.18M |
| Pretax Income | -11.29M |
| Net Income | -11.29M |
| EBITDA | -7.18M |
| EBIT | -7.18M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Total book value stands at -19.78M, with working capital of 7.68M providing operational flexibility.
| Cash & Cash Equivalents | 7.35M |
| Total Debt | N/A |
| Net Debt | -7.35M |
| Equity (Book Value) | -19.78M |
| Book Value Per Share | N/A |
| Working Capital | 7.68M |
Cash Flow
Klotho Neurosciences, Inc. produced -5.55M in operating cash flow over the past twelve months.
| Operating Cash Flow | -5.55M |
| Capital Expenditures | N/A |
| Free Cash Flow | -5.55M |
| FCF Per Share | N/A |
Scores
Klotho Neurosciences, Inc. posts an Altman Z-Score of -5.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.43 |